Tag: REOLYSIN

September 11, 2018

New Collaboration for Oncolytics Biotech and SOLTI

On Monday, Oncolytics Biotech announced the details of a new collaboration for its Phase 3 clinical trial.
September 10, 2018

Oncolytics Biotech Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a clinical...
July 3, 2018

4 Top Biotech Stocks on the TSX of Q2 2018

Which biotech stocks on the TSX have performed the best year-to-date? These four companies have risen to the top of...
March 19, 2018

What is Oncology Investing?

What is oncology investing? This sector can be intimidating for investors first getting into the space — here's a brief breakdown...
January 31, 2018

Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market

Oncolytics Biotech (TSX: ONC), a biotech company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate...
December 26, 2017

Biotech Outlook 2018: New Partnerships Seeking Consolidation in an Expansive Market

Mergers and acquisitions across the board, alongside a new tax plan, could spark new highs for the biotech industry in...
December 19, 2017

Top Biotech Stocks of 2017

Nearing the end of the year INN takes a look at the top gaining biotech stocks in the mid to...